Several major medical organizations recommend routine screening for unhealthy alcohol use. In this test specific episode of the "Answers From the Lab" podcast, Paul Jannetto, Ph.D., describes Mayo Clinic Laboratories' new direct biomarker test for alcohol consumption, PETH. This blood test has a much longer window of detection than existing urine tests for alcohol use.

"Alcohol is the most commonly abused drug in the world, and excessive alcohol use is the leading preventable cause of death in the United States," Dr. Jannetto says. "Routine screening and behavioral intervention for alcohol misuse is one of the most cost-effective clinical preventive services."

The preferred screening approach for ethanol — the chemical term for alcohol — measures certain substances that the body produces when ethanol is metabolized. The direct ethanol metabolites  (i.e., ethyl glucuronide and ethyl sulfate) currently used for alcohol testing can be detected in urine for up to five days.

PETH measures a different alcohol metabolite, known as phosphatidylethanol (PEth), in whole blood. "This new biomarker gives a window of detection of approximately two to four weeks in blood. The window can be longer in individuals who chronically or excessively consume alcohol," Dr. Jannetto says.

Listen to learn more about how PETH provides enhanced screening for alcohol consumption.

Note: Podcasts will not playback on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.

Testing

PETH | Phosphatidylethanol Confirmation, Blood

Useful information

This assay is designed to quantify two homologues of phosphatidylethanol (PEth) in whole blood collected in EDTA vacutainer tubes. The report is intended for use by physicians to verify abstinence or use of ethanol especially in liver transplant candidates/patients.

Specimen requirements

• Specimen Type: Whole Blood
  • Frozen (Preferred) 21 days
  • Refrigerated 7 days
• Container/Tube: Lavender Top (EDTA)
• Specimen Volume: 1 mL
• Specimen Minimum Volume: 0.5 mL

Performance information

Analytic time: 2 days

Days performed: Monday through Friday (8 a.m.)

The latest

Assay provides quick diagnosis of VEXAS syndrome: David S. Viswanatha, M.D.

April 30, 2024

David S. Viswanatha, M.D., explains how Mayo Clinic Laboratories' new assay provides rapid, definitive diagnosis of VEXAS, a recently identified syndrome affecting older men. Early diagnosis is key to managing the syndrome, which severely impacts multiple organs and blood.

Assay identifies patients eligible for new ovarian cancer drug: Maryam Shahi, M.D.

April 23, 2024

Maryam Shahi, M.D., explains how Mayo Clinic Laboratories' unique biomarker test (TEST ID: AFOLR) determines which patients would likely benefit from a new treatment for recurrent epithelial ovarian cancer. Disease recurrence is common, and about one-third of patients respond to the new medication.

Assay monitors response to monoclonal antibody therapy: Maria Alice Willrich, Ph.D.

April 16, 2024

Maria Alice Willrich, Ph.D., explains how Mayo Clinic Laboratories' new assay provides therapeutic drug monitoring of risankizumab, or RISA. Test results help guide care for patients with plaque psoriasis, psoriatic arthritis, and Crohn's disease.

View MoreView Less